New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News For GSK;GSK;FOLD;FOLD;CBST;CBST From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
December 8, 2014
17:30 EDTCBSTMerck acquisition of Cubist could be a 'winner', Barron's says
Subscribe for More Information
17:30 EDTCBSTMerck shares lower after reports of judge decision in Cubist/Hospira case
Subscribe for More Information
17:03 EDTCBSTJudge may have found in favor of Hospira in Cubist case,CNBC's Meg Tirrell says
CNBC's Meg Tirrell said in a tweet: "Whoa. $CBST Hospira decision out -- "appears judge may have found in favor of Hospira on several points," ISI's @MarkSchoenebaum says." Reference Link
16:24 EDTCBSTOn The Fly: Closing Wrap
Stocks on Wall Street were lower amid another drop in crude oil prices, which tumbled to five-year lows. The market opened slightly lower following weaker than expected data from China and Japan, with nothing of note on the domestic calendar to get buyers involved in the day’s activity. Near noon, the averages gained downside momentum and though the market pared its losses several times, it was never able to gain any steam to pull the indexes back into the green. ECONOMIC EVENTS: In the U.S., no major economic data was released. In Asia, Chinese exports rose 4.7% from a year earlier in November, which missed the consensus estimate for an 8% increase. Chinese imports fell 6.7% from the prior year last month, compared with projections for a 3.8% increase. Additionally, Japan's revised third quarter gross domestic product estimate showed the economy shrank more than initially thought, with growth contracting an annualized 1.9%. COMPANY NEWS: Shares of Cubist Pharmaceuticals (CBST) surged $26.24, or 35.29%, to $100.60 after Merck (MRK) agreed to acquire the maker of next-generation antibiotics for $102 per share in cash, or $8.4B and the assumption of $1.1B in debt. A number of other antibiotic makers also climbed, including Tetraphase (TTPH), which rose $2.45, or 8.82%, to $30.24, and Cempra (CEMP), which advanced $1.64, or 11.37%, to $16.06, while shares of Merck finished fractionally higher, adding 39c, or 0.63%, to $61.88 following the deal announcement. MAJOR MOVERS: Among the notable gainers following their presentations at the American Society of Hematology, or ASH, annual meeting were Calithera Biosciences (CALA), which gained $2.38, or 22.52%, to $12.95, and Acceleron Pharma (XLRN), which jumped $5.11, or 13.6%, to $42.67. Among the noteworthy losers was McDonald's (MCD), which fell $3.70, or 3.84%, to $92.61 after the Dow member reported a 2.2% decline in global same-restaurant sales in November. Additionally, the fast-food giant warned that its fourth quarter results would be hurt by its sales pressures, supplier issues in China and a stronger U.S. dollar. Also lower were shares of Liquidity Services (LQDT), which plunged $2.77, or 27.0%, to $7.49 after the company disclosed that Wal-Mart (WMT) had terminated a deal to provide it with surplus merchandise. INDEXES: The Dow fell 106.31, or 0.59%, to 17,852.48, the Nasdaq dropped 40.06, or 0.84%, to 4,740.69, and the S&P 500 slipped 15.06, or 0.73%, to 2,060.31.
14:28 EDTCBSTCubist downgraded to Neutral from Buy at SunTrust
Subscribe for More Information
13:32 EDTGSKEpizyme announces results for PRMT5 inhibitor
Subscribe for More Information
13:12 EDTCBSTMerck paid full price but made good deal for Cubist, says UBS
Subscribe for More Information
12:40 EDTCBSTOn The Fly: Midday Wrap
Subscribe for More Information
12:25 EDTCBSTAntibiotic makers rise after Merck agrees to buy Cubist
Subscribe for More Information
10:11 EDTCBSTHigh option volume stocks
Subscribe for More Information
09:20 EDTCBSTOn The Fly: Pre-market Movers
Subscribe for More Information
08:30 EDTCBSTMerck says deals with Cubist includes $250M break-up fee clause
Subscribe for More Information
08:21 EDTCBSTMerck says looked at all risks, including patent litgation, before Cubist deal
Subscribe for More Information
08:11 EDTCBSTCubist volatility elevated into Merck acquiring for $8.4B in cash
Subscribe for More Information
08:08 EDTCBSTMerck says about $9.5B of debt to be issued related to Cubist deal
Subscribe for More Information
07:13 EDTCBSTMerck to host conference call
Subscribe for More Information
07:01 EDTCBSTMerck to acquire Cubist for $102 per share in cash, or $9.5B
Subscribe for More Information
07:00 EDTCBSTMerck to acquire Cubist for $102 per share in cash
Subscribe for More Information
December 7, 2014
16:29 EDTCBSTMerck in discussions to buy Cubist for $7B, Bloomberg reports
Subscribe for More Information
December 5, 2014
06:04 EDTGSKGSK won't pursue divestment of certain brands in established products portfolio
As announced at the company’s Q2 results in July, GSK started a process to consider the divestment of certain North American and European brands in its Established Products Portfolio.The company has evaluated all bids received and has concluded, consistent with its key criteria of maximizing shareholder value, not to pursue divestment of these products.
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use